Tenured Associate Professor of Psychology, Tenured Associate Professor of Psychiatry

Contact

Office Location:

UHC Room 1415

Phone:
  • (802) 656-8714

Education

  • B.A. University of North Carolina at Chapel Hill, 1995
  • M.A. University of Vermont, 1999
  • Ph.D. University of Vermont, 2002
  • NIH Postdoctoral Fellowship at Johns Hopkins University School of Medicine

Curriculum vitae

PDF icon Sigmon_CV_1-2-2020.pdf

Research and/or Creative Works

Behavioral and pharmacological treatment of opioid dependence; Novel formulations of pharmacotherapies for opioid dependence; Smoking cessation among opioid-dependent patients using a behavioral approach; Laboratory models for understanding the interactions between stimulant medications, including nicotine, cocaine, d-amphetamine and methylphenidate; Behavioral treatments of substance use/abuse among individuals with serious mental illness.

Associations and Affiliations

Director, The Chittenden Clinic: Opioid Treatment Program

Director, UVM Center on Rural Addictions (CORA)

Faculty, Vermont Center on Behavior and Health (VCBH)

Faculty, VCBH Training Programs in Behavioral Pharmacology of Drug Dependence and Tobacco Regulatory Science

 

Publications

  • Streck, J.M., Sigmon, S.C., Priest, J., Bergeria, C.L., Davis, D.R., Hughes, J.R., Villanti, A.C., Tidey, J.W., Heil, S.H., Gaalema, D.E., Stitzer, M.L., & Higgins, S.T. (2020). Investigating tobacco withdrawal in response to reduced nicotine cigarettes among smokers with opioid use disorder and other vulnerabilities. Experimental and Clinical Psychopharmacology Feb. 6:10.1037/pha0000350.
  • Ochalek, T.A., Parker, M.A., Higgins, S.T. & Sigmon, S.C. (2019). Fentanyl exposure among patients seeking opioid treatment. Journal of Substance Abuse Treatment, 96, 23- 25.
  • Streck, J., Ochalek, T., & Sigmon, S.C. (2018). Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms. Experimental and Clinical Psychopharmacology, 26, 403-409.
  • Parker, M.A., Ochalek, T.A., Rose, G.L., Badger, G.J., & Sigmon, S.C. (2018). Feasibility of an Interactive Voice Response system for daily monitoring of illicit opioid use during buprenorphine treatment. Psychology of Addictive Behaviors, 32, 956-960.
  • Ochalek, T., Heil, S.H., Higgins S.T., Badger, G.J. & Sigmon, S.C. (2018). A novel mHealth application for improving HIV and Hepatitis C knowledge in individuals with opioid use disorder: A pilot study. Drug and Alcohol Dependence, 190, 224-228.
  • Higgins, S.T., Heil, S.H., Sigmon, S.C., Tidey, J.W., Gaalema, D.E., Stitzer, M.L., Durand, H., Bunn, J.Y., Priest, J.S., Arger, C.A., Miller, M.E., Bergeria, C.L., Davis, D.R., Streck, J.M., Zvorsky, I., Redner, R., Vandrey, R. & Pacek, L.R. (2017). Response to varying the nicotine content level of cigarettes in vulnerable populations: An initial experimental examination of acute effects. Psychopharmacology, 234, 89-98.
  • Higgins, S.T., Heil, S.H., Sigmon, S.C., Tidey, J.W., Gaalema, D.E., Hughes, J.R., Stitzer, M.L., Durand, H., Bunn, J.Y., Priest, J.S., Arger, C.A., Miller, M.E., Bergeria, C.L., Davis, D.R., Streck, J.M., Reed, D.D., Skelly, J.M., & Tursi, L. (2017). Addiction potential of reduced nicotine content cigarettes in populations with psychiatric disorders and other vulnerabilities to tobacco addiction. JAMA Psychiatry, 74, 1056-1064.
  • Brooklyn, J.R. & Sigmon, S.C. (2017). Vermont hub-and-spoke model of care for opioid use disorders: Development, implementation and impact. Journal of Addiction Medicine, 11, 286-292.
  • Sigmon, S.C., Ochalek, T., Meyer, A., Hruska, B., Heil, S.H., Badger, G.J., Rose, G., Brooklyn, J.R., Schwartz, R.P., Moore, B.A. & Higgins, S.T. (2016). Interim buprenorphine vs. waiting list for opioid dependence. The New England Journal of Medicine, 375, 2504-2505.